- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02037646
Quantitative Versus Qualitative Fecal Immunochemical Tests (FIT) to Prioritize Urgency of Colonoscopy Referral
Evaluating the Effectiveness of Screening Strategies Using Quantitative Versus Qualitative Fecal Immunochemical Test (FIT) to Prioritize Urgency of Colonoscopy Referral - a Randomized Controlled Trial Protocol
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Kuala Lumpur, Malaysia, 59100
- University of Malaya Medical Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults aged 50 years and above
Exclusion Criteria:
- Lower gastrointestinal tract symptoms such as diarrhoea, constipation, per rectal bleeding
- Personal history of colorectal tumour or cancer
- Family history of familial adenomatous polyposis or hereditary non-polyposis colorectal cancer
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Screening
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Qualitative fecal immunochemical test
Stool samples will be tested with the qualitative fecal immunochemical test (qFIT), and will be stratified for colonoscopy as follows: >200 ng/dL - colonoscopy with one month 100-200 ng/dL - colonoscopy as per waiting list <100 ng/dL - no colonoscopy Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients. |
This test measures the amount of blood within the submitted stool specimen
Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
Hospital Anxiety and Depression Scale (HADS) questionnaire
A 5-point patient satisfaction score will be documented at each patient visit related to screening.
|
|
Andet: Quantitative fecal immunochemical test
Stool samples will be tested with the quantitative fecal immunochemical test (FIT), and will be scheduled for colonoscopy as follows: Positive - colonoscopy as per waiting list Negative - no colonoscopy Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients. |
Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
Hospital Anxiety and Depression Scale (HADS) questionnaire
A 5-point patient satisfaction score will be documented at each patient visit related to screening.
This test detects presence or absence of blood within a submitted stool specimen.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to diagnosis of advanced colorectal neoplasms
Tidsramme: 40-90 days from the time of enrolment
|
Measured as number of days from the time of enrolment until histological diagnosis of a colorectal neoplasm
|
40-90 days from the time of enrolment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Analysis of screening costs
Tidsramme: Up to 90 days following enrolment
|
Total costs incurred as a result of the screening process
|
Up to 90 days following enrolment
|
|
Patient anxiety levels
Tidsramme: Up to 90 days after enrolment
|
As measured by the Hospital Anxiety and Depression Scale (HADS)
|
Up to 90 days after enrolment
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: April C Roslani, MBBCh, University of Malaya Medical Centre
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 926.24
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kolorektal cancer
-
University of ArkansasRekrutteringColorectal cancer og inflammatorisk tarmsygdomForenede Stater
-
University Health Network, TorontoAstraZenecaAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Leiomyosarkom | Mismatch Reparation Proficient Colorectal CancerCanada
-
Stingray TherapeuticsRekrutteringRefractory Metastatic Microsatellite Stabil Colorectal Cancer (MSS-CRC)Forenede Stater
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaIkke rekrutterer endnuKolorektal kirurgi | Robotkirurgi | Colorectal cancer og inflammatorisk tarmsygdom
-
Tianjin Medical University Cancer Institute and...RekrutteringMSI-H Advanced Colorectal CancerKina
-
Bristol-Myers SquibbAfsluttetMikrosatellit stabil kolorektal cancer | Mismatch Reparation Proficient Colorectal Cancer | Mikrosatellit ustabil kolorektal cancer | Mismatch Reparation Manglende tyktarmskræftForenede Stater, Australien, Belgien, Canada, Irland, Italien, Spanien, Frankrig
-
Syndax PharmaceuticalsMerck Sharp & Dohme LLCAfsluttetMelanom | Ikke-småcellet lungekræft | Mismatch Reparation-Proficient Colorectal CancerForenede Stater
Kliniske forsøg med Qualitative fecal immunochemical test
-
H. Lee Moffitt Cancer Center and Research InstituteAmerican Cancer Society, Inc.AfsluttetKolorektal cancer | Kolorektalt karcinomForenede Stater